Table 1 The clinicopathological characteristics and USP13 expression of 499 patients with prostate cancer

n

249

250

T stage, n (%)

0.107

 T2

103 (20.9%)

86 (17.5%)

 T3

139 (28.3%)

153 (31.1%)

 T4

3 (0.6%)

8 (1.6%)

N stage, n (%)

0.032

 N0

172 (40.4%)

175 (41.1%)

 N1

28 (6.6%)

51 (12%)

M stage, n (%)

0.123

 M0

225 (49.1%)

230 (50.2%)

 M1

3 (0.7%)

0 (0%)

PSA(ng/ml), n (%)

0.243

  < 4

210 (47.5%)

205 (46.4%)

  > =4

10 (2.3%)

17 (3.8%)

Gleason score, n (%)

0.009

 6

32 (6.4%)

14 (2.8%)

 7

125 (25.1%)

122 (24.4%)

 8

35 (7%)

29 (5.8%)

 9

56 (11.2%)

82 (16.4%)

 10

1 (0.2%)

3 (0.6%)